International Vaccine Institute
501C3 Nonprofit Organization Information
International Vaccine Institute is a 501(c)(3) charitable nonprofit in Republic Of Korea (EIN 31-1621592). It has been tax-exempt since February 1999, and contributions to it are not tax-deductible. Its Form 990 for tax year 2024 reports total revenue of $68,966,984 and net assets of $94,592,624. TaxExemptWorld has Form 990s on file for 15 tax years (2009–2024). The IRS classifies its activity as Research Institutes and/or Public Policy Analysis (NTEE Q053).
Form 990 · Tax period ending Dec 2024 · Filed Nov 15, 2025 · From the IRS e-file data
Dollar amounts for every revenue and expense line are in the full 990 report.
Mission (as filed): TO DISCOVER, DEVELOP AND DELIVER SAFE, EFFECTIVE AND AFFORDABLE VACCINES FOR GLOBAL PUBLIC HEALTH. ITS VISION IS DEVELOPING COUNTRIES FREE OF SUFFERING FROM INFECTIOUS DISEASE.
THE PHASE II COMPONENT OF THE STUDY IS COMPLETED, AND THE INTERIM CLINICAL STUDY REPORT (CSR) FROM PHASE II (PARTS A AND B) IS AVAILABLE. BASED ON ADDITIONAL TESTING RESULTS OF DAYS 28 AND 56 OF PHASE 2 SUBGROUP SAMPLES, DATA FROM NHP PASSIVE TRANSFER STUDY, AND SAFETY DATA, A FINAL DECISION ON THE OPTIMAL DOSE FOR PART C WAS MADE, AND 40 UG WAS SELECTED. A CONSORTIUM CONSENSUS JUSTIFICATION MEMO OF FINAL DOSE SELECTION IS COMPLETED. PROTOCOL AMENDMENT V 5.0 CONTAINING THIS NEW INFORMATION WAS APPROVED BY LOCAL ECS AND NRAS. VIRTUAL PI MEETINGS WITH ALL SITES TO UPDATE PROGRAM STATUS AND PROJ…
BPCOV2 PROJECT - 2024 SUMMARY OF ACTIVITIES (REFERENCE YEAR 2024) IN 2024, THE BPCOV2 PROJECT ADVANCED PRE-CLINICAL DEVELOPMENT OF A NEXT-GENERATION PAN-CORONAVIRUS MRNA VACCINE PLATFORM SUPPORTED BY CEPI. PROJECT PARTNERS (UPENN, UNC, UC DAVIS, CHULA VRC, AND IVI) FOCUSED ON MRNA CONSTRUCT DESIGN AND PRODUCTION. MULTIPLE MRNA CONSTRUCTS WERE PRODUCED AND TESTED, INCLUDING SPIKE VARIANTS, CHIMERIC CONSTRUCTS, AND VLP PLATFORMS, FORMULATED WITH SM-102 TO ENABLE PLATFORM COMPARISON.
VAT0008 IS A PIVOTAL MULTI-COUNTRY PHASE 3, MULTI-STAGE, MODIFIED DOUBLE-BLIND AND MULTI-ARM STUDY WHERE EFFICACY, SAFETY AND IMMUNOGENICITY OF TWO SARS-COV-2 ADJUVANTED RECOMBINANT PROTEIN VACCINES (MONOVALENT AND BIVALENT) WERE TESTED AS PRIMARY SERIES AND MONOVALENT BOOSTER DOSE AS AN EXTENSION. IVI LED THE EFFORT IN NEPAL TO CONDUCT THE CLINICAL TRIAL INCLUDING CONDUCTING THE LOCAL DSMB MEETING. THE PRIMARY SERIES STUDY WAS INITIATED IN JULY 2021. THE FIRST SUBJECT FOR THE PRIMARY SERIES WAS ENROLLED IN SEPTEMBER 2021. THE CROSSOVER/BOOSTER PHASE STARTED IN JANUARY 2023. THE LAST SUBJECT …
ALL OTHER PROGRAMS
Public charity (509(a)(1), 170(b)(1)(A)(vi)) · 53.8% public support
Prepared by TaxExemptWorld from IRS Form 990 e-file data (object ID 202543199349303654). Not an official IRS form.